Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.77 |
| ▸ | LCK | P06239 | 1/20 | 0.77 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.70 |
| ▸ | NPY2R | P49146 | 4/20 | 0.50 |
| ▸ | NPY1R | P25929 | 2/20 | 0.50 |
| ▸ | NPY4R | P50391 | 2/20 | 0.50 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.50 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.44 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.43 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.43 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.43 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.43 |
| ▸ | FLT1 | P17948 | 1/20 | 0.42 |
| ▸ | VEGFA | P15692 | 6/20 | 0.41 |
| ▸ | KDM1A | O60341 | 2/20 | 0.40 |
| ▸ | RCOR1 | Q9UKL0 | 2/20 | 0.40 |
| ▸ | BECN1 | Q14457 | 1/20 | 0.39 |
| ▸ | TCF4 | P15884 | 1/20 | 0.39 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2274 | 0.92 | EGFR (0.86) | EGFRLCKHKDC1NPY2RNPY1R | |
| SCHEMBL1024602 | 0.92 | EGFR (0.86) | EGFRLCKHKDC1NPY2RNPY1R | |
| SCHEMBL4352461 | 0.92 | EGFR (0.86) | EGFRLCKHKDC1NPY2RNPY1R | |
| Zinc Ion SCHEMBL29426351 | 0.87 | HKDC1 (0.86) | EGFRLCKHKDC1NPY2RNPY1R | |
| Bacitracin SCHEMBL29603422 | 0.87 | EGFR (1.00) | EGFRLCKHKDC1NPY2RNPY1R | |
| Bacitracin SCHEMBL20385900 | 0.87 | EGFR (1.00) | EGFRLCKHKDC1NPY2RNPY1R | |
| SCHEMBL25547820 | 0.85 | EGFR (0.97) | EGFRLCKHKDC1NPY2RNPY1R | |
| SCHEMBL29542898 | 0.84 | EGFR (0.76) | EGFRLCKHKDC1NPY2RNPY1R | |
| SCHEMBL1059374 | 0.84 | EGFR (0.73) | EGFRLCKHKDC1NPY2RNPY1R | |
| SCHEMBL21413350 | 0.84 | EGFR (0.73) | EGFRLCKHKDC1NPY2RNPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230218726-A1 | TREATMENT OF VIRAL CONJUNCTIVITIS | OKOGEN, INC. | 2023-07-13 | — | — | US | disclosed |
| US-20090280069-A1 | PROGUANIL TO TREAT SKIN/MUCOSAL DISEASES | TOLMAR, INC. (US) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090280069-A1 | PROGUANIL TO TREAT SKIN/MUCOSAL DISEASES | PROKR1, PROKR2, MC1R | EGFR 677/4885LCK 2025/4885HKDC1 3542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.